A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Inclusion Criteria

* Legal age of consent and at least 18 years old
* Study 1 -

  * BMI ≥ 30 kg/m2 or
  * 25 kg/m2 ≤ BMI \< 30 kg/m2 with at least one of the following weight-related comorbidities:
  * Hypertension
  * Prediabetes
  * Dyslipidemia
  * Cardiovascular disease
  * Obstructive sleep apnea.
* Study 2 - BMI ≥ 25 kg/m2 and T2DM defined as below:

  * Established diagnosis of T2DM
  * Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol/mol) at the screening visit
* Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)
* History of at least one self-reported unsuccessful dietary effort to lose body weight.

Exclusion Criteria

* Study 1 - Established diagnosis of T1DM or T2DM.
* Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:

  * T1DM
  * HbA1c ≥ 10% (86 mmol/mol) at the screening visit
  * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema.
  * Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
* History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis
* History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2